MedTrace Logo

CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer

NCT07316309 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2026-01-05

No results posted yet for this study

Summary

This prospective observational study aims to evaluate the clinical value of CXCR4-targeted PET/CT imaging in patients with limited-stage small cell lung cancer (LS-SCLC).

Patients diagnosed with LS-SCLC at Shandong Cancer Hospital and Institute underwent \[18F\]AlF-NOTA-QHY-04 PET/CT imaging before receiving standard concurrent chemoradiotherapy. Imaging findings were analyzed and correlated with clinical outcomes, including progression-free survival, to explore the potential role of CXCR4 PET/CT as a prognostic imaging biomarker.

The results of this study may help improve risk stratification and outcome prediction in patients with limited-stage small cell lung cancer.

Conditions

Sponsors & Collaborators

  • Shandong Cancer Hospital and Institute

    lead OTHER

Principal Investigators

  • Jie Liu · Shandong Cancer Hospital and Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-28
Primary Completion
2024-07-19
Completion
2025-09-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07316309 on ClinicalTrials.gov